Data (Protection) in M&A Transactions
In order to expand their own businesses or to explore new business models, companies frequently acquire competitors or start-ups operating in the relevant fields and integrate them into their businesses. Data protection is playing an increasingly important role in the context of M&A transactions, because often the object of purchase cannot be clearly identified but rather is a structure comprising rights, technology, knowledge and infrastructure. In this regard, the question often arises whether the data underlying the asset (eg customer or supplier data) may be sold and transferred in a straightforward manner. Also, it will in future be necessary to clarify whether data represents an independent additional factor in determining a company's market power and thus may trigger a notification requirement with the competent cartel office under merger control rules.
Even the provision of personal employee or customer data in the data room as part of a due diligence may be deemed a transfer within the meaning of data protection law. Data pertaining to officers or directors may be governed by other rules, however. Restrictions under data protection law frequently undermine the legitimate interests of the purchaser for disclosure of relevant data in order to perform a risk analysis and gain a detailed overview of the target, and should be taken into account when acquiring a company. Although potential administrative fines for non-compliance of course do play a role, the risk that data collected unlawfully may have to be deleted and may no longer be used is even more important (as shown recently by the sanctions imposed by the Bavarian Data Protection Authority (Bayerisches Landesamt für Datenschutzaufsicht) regarding the unlawful transfer of data in connection with an asset deal).
News & insights
News: 09 SEPTEMBER 2020
Allen & Overy has advised Marel hf, a public limited company listed both on the Icelandic Nasdaq OMX and the Euronext Amsterdam and headquartered in Gardabaer, Iceland, on the acquisition of the…Read more
News: 20 JULY 2020
An A&O team comprising UK, German, U.S. and Dutch lawyers is advising GlaxoSmithKline (GSK) on its strategic collaboration with German biotech company CureVac for the research, development and…Read more
Publications: 19 JUNE 2020
What foreign investors need to consider Germany is one of the few countries in the world where the doors are wide open to foreign investment. With an export-oriented national economy, Germany thrives…Read more
Publications: 03 JUNE 2020
The German Foreign Direct Investment (FDI) screening rules were amended, bringing important parts of the health care sector under the regime applicable to critical infrastructure. Some, but not all,…Read more